Aim: To evaluate the incidence and risk of cardiac toxicities associated with panitumumab in
advanced cancer of Caucasian patients. Materials & methods: The incidence of cardiac …

Panitumumab is a human immunoglobulin monoclonal antibody designed to target the
epidermal growth factor receptor (EGFR) which is used in the treatment of metastatic …

Background Cardiotoxicity is a serious side effect of molecularly targeted agents. The
purpose of this study was to evaluate the incidence and Relative Risk (RR) of developing all …

Objective The cardiac safety of cetuximab and panitumumab, particularly as single agents,
has not been investigated extensively. This trial was designed to specifically evaluate the …

Tyrosine kinase inhibitors (TKIs) have transformed cancer treatment but are associated with
cardiovascular toxicity, including heart failure. This review examines the cardiotoxicity of …

6596 Background: Tyrosine kinase inhibitors (TKI) are cancer drugs associated with
cardiovascular events in clinical trials. There are limited data on the frequency of these …

Introduction: Pazopanib, a multi-target tyrosine-kinase inhibitor (TKI), is a relatively novel
anticancer agent registered for advanced renal cell carcinoma recently emerged in the …

We thank Dr Campiotti and colleagues for their interest in our point of view, which
highlighted achievements and unsettled issues emerging from the ESC position paper on …

Over the past decade, there has been a major shift in chemotherapy from non-specific
cytotoxic drugs to molecular targeted drug therapies. As more molecular targeted therapies …

Background: Target therapy can cause various cardiovascular complications. The aim of this
study was to evaluate the burden of cardiovascular complications related to treatment with …